JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer.

High JAK-STAT pathway activity in breast cancer correlates with improved immunotherapy response, especially in triple-negative breast cancer patients, serving as a predictive biomarker.

• Why it matters: Understanding JSP heterogeneity is crucial because its dynamic expression influences tumor progression and immune response, impacting the effectiveness of immunotherapy treatments.
• What they did: The study analyzed JSP expression across tumor and immune cells in breast cancer, revealing its association with malignant phenotypes, immune activity, and treatment outcomes, particularly in 3 datasets.
• The result: Findings suggest that targeting JSP requires a nuanced approach, as high JSP activity enhances anti-tumor immunity and immunotherapy efficacy, with STAT4 playing a dual role in tumor promotion and immune support.